|
Originally published In Press as doi:10.1074/jbc.M303657200 on May 20, 2003
J. Biol. Chem., Vol. 278, Issue 32, 30235-30247, August 8, 2003
Chondroitin Sulfate Synthase-2
MOLECULAR CLONING AND CHARACTERIZATION OF A NOVEL HUMAN GLYCOSYLTRANSFERASE HOMOLOGOUS TO CHONDROITIN SULFATE GLUCURONYLTRANSFERASE, WHICH HAS DUAL ENZYMATIC ACTIVITIES*
Toshikazu Yada ¶,
Masanori Gotoh ¶ || **,
Takashi Sato ||,
Masafumi Shionyu  ,
Mitiko Go  ,
Hiromi Kaseyama ,
Hiroko Iwasaki || **,
Norihiro Kikuchi ||  ,
Yeon-Dae Kwon ||  ,
Akira Togayachi || ¶¶,
Takashi Kudo ||,
Hideto Watanabe ,
Hisashi Narimatsu || and
Koji Kimata ||||
From the
Institute for Molecular Science of
Medicine, Aichi Medical University, Nagakute, Aichi 480-1195,
Seikagaku Corp., 1253 Tateno 3-Chome,
Higashi-yamato, Tokyo 207-0021, ||Glycogen
Functional Team, Research Center for Glycoscience, National Institute of
Advanced Industrial Science and Technology, OSL C-2, 1-1-1 Umezono, Tsukuba,
Ibaraki 305-8568, **Amersham Biosciences KK, 3-25-1,
Hyakunincho, Shinjuku-ku, Tokyo 169-0073,
 Division of Biological Science,
Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya,
Aichi 464-8602,  Mitsui Knowledge Industry
Co., Ltd., 1-32-2 Honcho, Nakano-ku, Tokyo 164-8721,
¶¶New Energy and Industrial Technology
Development Organization, Sunshine 60 Bldg., 3-1-1 Higashi Ikebukuro,
Toshima-ku, Tokyo 170-6028, Japan
Received for publication, April 8, 2003
, and in revised form, May 16, 2003.
 |
ABSTRACT
|
|---|
Chondroitin sulfate is found in a variety of tissues as proteoglycans and
consists of repeating disaccharide units of N-acetylgalactosamine and
glucuronic acid residues with sulfate residues at various places. We found a
novel human gene (GenBankTM accession number AB086063
[GenBank]
) that possesses a
sequence homologous with the human chondroitin sulfate glucuronyltransferase
gene which we recently cloned and characterized. The full-length open reading
frame encodes a typical type II membrane protein comprising 775 amino acids.
The protein had a domain containing 3-glycosyltransferase motif but
lacked a typical 4-glycosyltransferase motif, which is the same as
chondroitin sulfate glucuronyltransferase, whereas chondroitin synthase had
both domains. The putative catalytic domain was expressed in COS-7 cells as a
soluble enzyme. Surprisingly, both glucuronyltransferase and
N-acetylgalactosaminyltransferase activities were observed when
chondroitin, chondroitin sulfate, and their oligosaccharides were used as the
acceptor substrates. The reaction products were identified to have the linkage
of GlcUA 13GalNAc and GalNAc 14GlcUA at the
non-reducing terminus of chondroitin for glucuronyltransferase activity and
N-acetylgalactosaminyltransferase activity, respectively.
Quantitative real time PCR analysis revealed that the transcripts were
ubiquitously expressed in various human tissues but highly expressed in the
pancreas, ovary, placenta, small intestine, and stomach. These results
indicate that this enzyme could synthesize chondroitin sulfate chains as a
chondroitin sulfate synthase that has both glucuronyltransferase and
N-acetylgalactosaminyltransferase activities. Sequence analysis based
on three-dimensional structure revealed the presence of not typical but
significant 4-glycosyltransferase architecture.
 |
INTRODUCTION
|
|---|
Chondroitin sulfate
(CS)1 proteoglycans
are located in the extracellular matrix and on cell surfaces of various kinds
of human tissues. Some of the chondroitin sulfate proteoglycans provide high
osmotic pressure and water retention, and others modulate not only cell
adhesion to extracellular matrix, cell migration, cell proliferation, and
morphogenesis but also some cytokine signals
(1,
2). A few general features of
the biosynthetic assembly of chondroitin sulfate proteoglycans are as follows:
(i) the sequential synthesis of the core protein; (ii) xylosylation of
specific Ser moieties of the core protein; (iii) addition of two Gal residues
to the Xyl; (iv) completion of a common tetrasaccharide linkage region by
addition of a GlcUA residue; (v) addition of GalNAc residue to initiate the
chondroitin/dermatan sulfate biosynthesis; (vi) repeated addition of GlcUA
residues alternating with GalNAc residues to grow to the large heteropolymer
glycosaminoglycan chains; and (vii) modification of these growing
glycosaminoglycan chains by O-sulfation at various places, and by
epimerization of some of GlcUA residues to IdoUA residues.
The assembly of the linkage region on the core protein followed by
glycosaminoglycan polymerization and modification occurs in the intracellular
membrane system composed of the endoplasmic reticulum and Golgi apparatus
(3,
4). With the exception of the
polysaccharide chain-initiating Xyl transferase, which is found partially in
the endoplasmic reticulum (5),
all the enzymes are firmly attached to the Golgi membranes and may work in an
orchestrated manner, but some are found in serum or the culture medium of
cells (4,
6). The enzymes responsible for
the synthesis of the linkage region of proteoglycans, Xyl transferase
(7), Gal transferase I
(8,
9), Gal transferase II
(10), and GlcUA transferase I
(11,
12), which act sequentially to
transfer Xyl, Gal, Gal, and GlcUA from their respective sugar nucleotide
precursors to the acceptor core protein, have been cloned. We have been
interested in the modification reactions, especially sulfations, because
specific regional structures raised by the modifications determine the
capacity of chondroitin sulfate to interact with other molecules including
cytokines and regulate their assembly and activities in extracellular and
pericellular matrices
(1318).
Except for chondroitin C5-epimerase, most of modifying enzymes for chondroitin
sulfate biosynthesis, such as chondroitin O-sulfotransferases
including chondroitin 4-O-sulfotransferase
(19), chondroitin
6-O-sulfotransferase
(20), uronyl
2-O-sulfotransferase
(21), and
N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase
(22), have been cloned. The
sulfation of chondroitin sulfate ordinarily proceeds together with
polymerization at the Golgi apparatus. Thus, in order to address control
mechanisms of the sulfation, we should also study the enzymes for the chain
synthesis, especially chondroitin sulfate elongation enzymes.
Recent progress with the human genome project and the expansion of other
data bases such as expressed sequence tags (ESTs) and full-length cDNAs has
enabled the search for novel genes that are homologous to known genes.
Kitagawa et al. (23)
identified a human chondroitin synthase, from the HUGE (human
unidentified gene-encoded large proteins)
protein data base by screening with the keywords "one transmembrane
domain" and "galactosyltransferase family." This enzyme had
the dual glycosyltransferase activities of glucuronyltransferase II (GlcAT-II)
and N-acetylgalactosaminyltransferase II (GalNAcT-II) responsible for
synthesizing the repeated disaccharide units of chondroitin sulfate
(23). By a similar homology
search of the data bases, four enzymes including chondroitin synthase have
further been cloned and characterized. Chondroitin sulfate GalNAcT-1
(CSGalNAcT-1) and chondroitin sulfate GalNAcT-2 (CSGalNAcT-2), the second and
fourth chondroitin glycosyltransferases cloned, respectively, exhibit both
GalNAcT-II activity for chain elongation and GalNAcT-I activity that determine
and initiate the synthesis of chondroitin sulfate in the common linkage region
(2427).
Chondroitin sulfate GlcUA transferase (CSGlcAT), the third chondroitin
glycosyltransferase cloned, has only GlcAT-II activity, which has been
proposed to be involved in chain elongation
(28). Therefore, more than
four enzymes are likely responsible for chondroitin/dermatan sulfate
biosynthesis, and they form a gene family, like the EXT family for
heparin/heparan sulfate biosynthesis
(29).
In the present study, a search of the data bases using the amino acid
sequence of CSGlcAT revealed a novel gene whose product was characterized as
the fifth enzyme to possess high homology with CSGlcAT. Interestingly, despite
its homology with CSGlcAT, this enzyme, designated CSS2, shows both GlcAT-II
and GalNAcT-II activity toward the non-reducing terminal residue of
chondroitin/chondroitin sulfate with the specific linkage structure.
 |
EXPERIMENTAL PROCEDURES
|
|---|
MaterialsUDP-[14C]GlcUA (313 mCi/mmol) and
UDP-[3H]Gal (20 Ci/mmol) were purchased from ICN Biomedicals
(Irvine, CA) and ARC (St. Louis, MO), respectively. UDP-[3H]GalNAc
(7.0 Ci/mmol) and UDP-[14C]GlcNAc (200 mCi/mmol) were from
PerkinElmer Life Sciences. Chondroitin (a chemically desulfated derivative of
whale cartilage chondroitin sulfate A), chondroitin sulfate A (whale
cartilage), dermatan sulfate (pig skin), chondroitin sulfate C (shark
cartilage), chondroitin sulfate D (shark cartilage), chondroitin sulfate E
(squid cartilage), hyaluronan (rooster comb), heparan sulfate (pig aorta),
-N-acetylgalactosaminidase (EC 3.2.1.49
[EC]
from
Acremonium sp.), and chondroitinase ACII (EC 4.2.2.5
[EC]
from
Arthrobacter aurescens) were from Seikagaku Corp. (Tokyo, Japan).
Testicular hyaluronidase (EC 3.2.1.35
[EC]
, H6254, type V from sheep testes),
-glucuronidase (EC 3.2.1.31
[EC]
, G0501, type B-10, from bovine liver),
heparin (bovine intestine), Gal 13GalNAc -O-benzyl,
D-GlcUA -O-4-nitrophenyl, anti-FLAG BioM2
antibody, anti-FLAG M2-agarose gel, and pFLAG-CMV1 were from Sigma. A pcDNA3.1
was from Invitrogen. A SuperdexTM peptide HR10/30 column, HiLoad 16/60
Superdex 30-pg column, Fast Desalting column HR10/10, and PD10 desalting
column were purchased from Amersham Biosciences. N-Acetyl heparosan,
GlcNAc -O-benzyl, GlcNAc -O-benzyl,
Gal -O-benzyl, Gal -O-benzyl,
GalNAc -O-benzyl, GalNAc -O-benzyl,
Gal 13Gal 14Xyl 1-O-methoxyphenyl,
GlcUA 13Gal 13Gal 14Xyl 1-O-methoxyphenyl,
and Gal 14GlcNAc 13Gal 14GlcNAc were
kindly provided by Seikagaku Corp.
Construction of CSS2 Expression VectorWe performed a BLAST
search of the EST data bases using the amino acid sequence of the cloned human
CSGlcAT as a query, and we found a novel EST clone (GenBankTM accession
number NM_018590
[GenBank]
) (28). As the
sequence was not complete, a GeneScan search was performed on the human
genomic data bases. The predicted sequence was confirmed by PCR with two
primers, 5'-ACTCCTCTGGCTGCTCTGGGGGTTCG-3' and
5'-TCTGGTTTTGGGGGAGAAGTGG-3' (GenBankTM accession number
AB086063
[GenBank]
). The putative catalytic domain of the enzyme (amino acids
97775) was expressed as a secreted protein fused with a FLAG peptide in
COS-7 cells. An 2.0-kb DNA fragment was amplified by PCR using the
Marathon-ReadyTM cDNA derived from human brain (Clontech), as a template,
and two primers, 5'-GGAATTCCGGCCAGGCCGCCAAAAAGGC-3' and
5'-CGGGATCCTCAGGTGCTGTTGCCCTGCTCC-3'. The amplified fragment was
inserted between EcoRI and BamHI sites of pFLAG-CMV-1
(Sigma).
Purification of FLAG-tagged Recombinant Enzyme from Culture
SupernatantsCOS-7 cells (ATCC CRL-1651) were co-transfected with
the expression plasmid and pcDNA3.1 using TransFastTM (Promega, Madison,
WI) according to the manufacturer's instructions. The stable transfectants
were selected with 600 µg/ml G418 in Dulbecco's modified Eagle's medium
containing 10% (v/v) fetal bovine serum (HyClone Laboratories, Logan, UT), 100
µg/ml streptomycin sulfate, and 100 units/ml penicillin G and cloned by
limiting dilution. Cloned cell lines were tested for synthesis and secretion
of the recombinant protein by immunoprecipitation and Western blotting using
an anti-FLAG BioM2 antibody (Sigma). The secreted enzyme was purified by
affinity chromatography using anti-FLAG M2-agarose gel (Sigma). The
conditioned medium and gel were mixed overnight at 4 °C and centrifuged
for 5 min, and the supernatants were aspirated. The gel was washed five times
with 10 ml of 20% (v/v) glycerol in 50 mM Tris-HCl, pH 7.4, and
resuspended in the same buffer containing protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, and 1 µg/ml pepstatin
A) to produce a 50% slurry
(28). The immobilized enzyme
was stable at 4 °C for at least 4 weeks. The amount of recombinant protein
recovered was estimated by immunoblotting. FLAG-tagged bacterial alkaline
phosphatase (Met-FLAG-BAP, molecular mass of 49 kDa) was used as a standard to
estimate the relative amount, as described previously
(28). The amount of
recombinant enzyme protein is expressed in arbitrary units, with each unit of
intensity equivalent to 10 ng of FLAG-tagged BAP protein
(28).
Preparation of Acceptor SubstrateGlycosaminoglycan polymers
were purchased from Seikagaku Corp. For GlcAT-II assay, chondroitin sulfate
AE, chondroitin, hyaluronan, heparan sulfate, and
N-acetyl-heparosan were digested with -glucuronidase prior to
the assay (28). Briefly, 1 mg
of each polymer was digested with 100 units of -glucuronidase in a total
volume of 1 ml of 100 mM sodium acetate buffer, pH 5.0, at 37
°C overnight. The digests were then boiled for 20 min; the denatured
enzyme was removed by trichloroacetic acid precipitation from the resultant
supernatants that were neutralized with sodium hydroxide, and the
glycosaminoglycans were recovered by ethanol precipitation. The
glycosaminoglycans were redissolved with distilled water of a concentration of
10 mg/ml. Oligosaccharides of chondroitin sulfate, chondroitin, and hyaluronan
were prepared as described previously
(28). Briefly, for the
preparation of the oligosaccharides with even numbers (4-, 6-, 8-, 10-, 12-,
and 14-saccharides), each polymer (10 mg) was partially digested with 1,000
turbidity reducing units of testicular hyaluronidase in 1 ml of 0.1
M sodium acetate buffer, pH 5.2, containing 0.15 M NaCl
at 37 °C for the appropriate incubation times. For the preparation of the
oligosaccharides with odd numbers (5-, 7-, 9-, 11-, and 13-saccharides), the
hyaluronidase digests were boiled for 20 min and further digested with 1,000
units of -glucuronidase (EC 3.2.1.31
[EC]
, from bovine liver, Sigma) at 37
°C for 24 h. After inactivation of the enzyme by boiling for 10 min and
centrifuging at 10,000 x g for 20 min at 4 °C, the
supernatants of the digests were fractionated on the HiLoad 16/60 Superdex
30-pg column (16 x 600 mm) with 0.2 M
NH4HCO3 at a flow rate of 2 ml per min, and absorbance
was monitored at 225 nm. The peak fractions were pooled, and desalted on the
PD10 desalting column with distilled water as an eluate. The uronic acid
contents were then determined by the Bitter-Muir's method using
D-glucuronic acid as a standard
(30). The desalted solution
was lyophilized and redissolved in distilled water at a concentration of 1
mM for each oligosaccharide.
Glycosyltransferase AssaysThe glycosyltransferase
activities were investigated with radioactive forms of UDP-GlcUA, UDP-GalNAc,
UDP-GlcNAc, UDP-Gal, and various acceptor saccharide substrates, including
polymer chondroitin, various chondroitin sulfate isoforms, hyaluronan, heparan
sulfate, heparin (100 µg each), oligosaccharides of chondroitin,
chondroitin sulfate isoforms, and hyaluronan (1 nmol each). The standard
reaction mixture for GalNAcT-II contained 10 µl of the resuspended beads
and acceptor substrate, 0.32 nmol of UDP-[3H]GalNAc (6.66 x
105 dpm), 50 mM MES, pH 6.2, and 10 mM
MnCl2 in a total volume of 30 µl. The reaction mixture for
GlcAT-II contained 10 µl of the resuspended gel and the acceptor substrate,
0.307 nmol of UDP-[14C]GlcUA (2.22 x 105 dpm), 50
mM MES, pH 6.2, and 10 mM MnCl2 in a total
volume of 30 µl. The reaction mixtures were incubated at 37 °C for 1 h
with mixing, and the reaction was stopped by boiling for 5 min, and then
radiolabeled products were separated from free UDP-[3H]GalNAc or
UDP-[14C]GlcUA by gel filtration using SuperdexTM peptide
HR10/30 column (10 x 300 mm) with 0.2 M NaCl as an eluant or
HiLoad 16/60 Superdex 30-pg column (16 x 600 mm) with 0.2 M
NH4HCO3 as an eluate
(28). The labeled products
recovered were quantified by liquid scintillation counting. For the acceptor
substrates of oligosaccharide with an aromatic residue (methoxyphenyl- or
benzyl-) at the reducing terminus, reaction products were diluted with 1 ml of
0.5 M NaCl and applied to a Sep-Pak C18 cartridge (100 mg; Waters,
Milford, MA) (28). The
cartridge was washed with 3 ml of 0.5 M NaCl and then 3 ml of
water; the product was eluted with 50% methanol, and the radioactivity of all
fractions was measured by liquid scintillation counting. In repetitions of the
experiments when different batches of the enzyme were used, an aliquot was
first analyzed by SDS-PAGE and Western blotting using anti-FLAG BioM2 antibody
with FLAG-BAP as a standard to obtain a comparable amount of enzyme.
Identification of the Enzyme Reaction ProductsEach product
from the GlcAT-II reaction using chondroitin or CS11 and the GalNAcT-II
reaction using chondroitin was isolated by gel filtration column
chromatography using the Superdex Peptide HR10/30 column. The radioactive peak
containing the product was pooled and desalted with the Fast Desalting column
HR10/10 using distilled water as an eluant and lyophilized. In order to
identify the linkage, the dried sample (about 20 pmol of radiolabeled
material) from GlcAT-II reactions was incubated with 100 milliunits of
chondroitinase ACII in a total volume of 100 µl of 100 mM
Tris-HCl, pH 7.4, containing 30 mM sodium acetate at 37 °C for
1 h or 1 unit of -glucuronidase in a total volume of 100 µl of 100
mM sodium acetate buffer, pH 5.0, at 37 °C overnight. For
confirmation of the linkage structure, we determined whether the product could
serve as an acceptor for Escherichia coli strain K4 chondroitin
polymerase, which synthesizes chondroitin, and the resultant products could be
digested with chondroitinase ACII completely
(31). Briefly, the 20 pmol of
radiolabeled materials was lyophilized and served as substrate for K4
chondroitin polymerase. The reaction was performed at 30 °C overnight in a
50-µl solution containing 50 mM Tris-HCl, pH 7.2, 20
mM MnCl2, 0.1 M
(NH4)2SO4,1 M ethylene glycol, 20
pmol of radiolabeled [14C]CS12, 30 nmol each of UDP-GlcUA and
UDP-GalNAc, and 0.8 µg of the enzyme preparation. This was followed by
boiling for 5 min to stop the reaction. The radioactive peak containing the
product was pooled and desalted with the Fast Desalting column HR10/10 using
distilled water as an eluant and lyophilized. The dried sample (about 20 pmol
of radiolabeled material) from the E. coli strain K4 chondroitin
polymerase reaction was incubated with 100 milliunits of chondroitinase ACII
in a total volume of 100 µl of 100 mM Tris-HCl, pH 7.4,
containing 30 mM sodium acetate at 37 °C for 1 h. The enzyme
digests were analyzed again using the same Superdex Peptide HR10/30 column as
described above. In order to identify the linkage, the dried sample (about 20
pmol of radiolabeled material) from GalNAcT-II reactions was incubated with
100 milliunits of chondroitinase ACII in a total volume of 100 µl of 100
mM Tris-HCl, pH 7.4, containing 30 mM sodium acetate at
37 °C for 1 h or 100 milliunits of
-N-acetylgalactosaminidase in a total volume of 100
µlof50mM sodium citrate buffer, pH 4.5, at 37 °C overnight.
The enzyme digests were analyzed again using the same Superdex Peptide HR10/30
column as described above.
Quantitative Analysis of the CSS2 Transcript in Human Tissues by Real
Time PCRFor quantification of CSS2 transcripts, we employed the
real time PCR method, as described in detail previously
(32). Marathon Ready cDNA
derived from various human tissues was purchased from Clontech. Standard
curves for the endogenous control, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA, were generated by serial dilution of pCR2.1 (Invitrogen) DNA
containing the GAPDH gene. The primer set and the probe for CSS2 were
as follows: the forward primer, 5'-GCTGAACTGGAACGCACGTA-3', and
the reverse primer, 5'-CGGGATGGTGCTGGAATAC-3', and the probe,
5'-AGATCCAGGAGTTACAGTGG-3', with a minor groove binder. The primer
sets and the probes for CSGlcAT and CSS1 were as follows: the forward primer
for CSGlcAT, 5'-GTGAAATAGAACAACTGCAGGCTC-3', and the reverse
primer for CSGlcAT, 5'-GAGAAGGTGTGCTGCTCTGTGA-3', the probe for
CSGlcAT, 5'-CGGAACCTGACCGTGC-3', with a minor groove binder; the
forward primer for CSS1, 5'-AGTGTGTCTGGTCTTATGAGATGCA-3', and the
reverse primer for CSS1, 5'-AGCTGTGGAGCCTGTACTGGTAG-3' and the
probe for CSS1, 5'-ATGAGAATTACGAGCAGAAC-3' with a minor groove
binder. PCR products were continuously measured with an ABI PRISM 7700
Sequence Detection System (Applied Biosystems, Foster City, CA). The relative
amounts of their transcripts were normalized to the amount of GAPDH transcript
in the same cDNA.
Comparison of the C-terminal Domain Structure between CSS2 and CSGlcAT
by Homology ModelingThe molecular structures of the C-terminal
halves of CSS2 (C-CSS2; amino acid residues 474775) and CSGlcAT
(C-CSGlcAT; amino acid residues 455772) were estimated from the model
of the C-terminal half of CSS1 (C-CSS1; amino acid residues 500802)
because the amino acid sequences of C-CSS2 and C-CSGlcAT are far diverged from
other glycosyltransferases for which the three-dimensional structures are
known. From the consensus result of three threading methods, 3D-PSSM
(www.sbg.bio.ic.uk/~3dpssm/),
FUGUE
(www-cryst.bioc.cam.ac.uk/~fugue/prfsearch.html),
and GenTHREADER
(bioinf.cs.ucl.ac.uk/psiform.html),
we chose bovine 4-galactosyltransferase ( 4GalT-1) as a template
for homology modeling of C-CSS1, because 4GalT-1 obtained the best score
by 3D-PSSM and FUGUE and the second highest score by GenTHREADER. Furthermore,
CSS1 has been classified into the same glycosyltransferase family (Family GT7)
with 4GalT-1 by CAZy
(afmb.cnrs-mrs.fr/~cazy/CAZY/index.html),
in which CSGalNAcT-1 and CSGalNAcT-2 are also the same family members. With
the pairwise alignment of C-CSS1 and 4GalT-1 derived from 3D-PSSM,
homology modeling of C-CSS1 was performed using FAMS
(33). Then the amino acid
sequences of C-CSS1, C-CSS2, C-CSGlcAT, CSGalNAcT-1 (amino acid residues
228532), and CSGalNAcT-2 (amino acid residues 237542) were
aligned using ClustalW (34)
and joined to the pairwise alignment of C-CSS1 and 4GalT-1. The
secondary structures of bovine 4GalT-1 corresponded well with those
predicted by PSIPRED2 (35) for
C-CSS2 and C-CSGlcAT as well as CSGalNAcT-1 and CSGalNAcT-2. By using the
pairwise alignment of C-CSS1 and C-CSS2 and that of C-CSS1 and C-CSGlcAT
extracted from the multiple alignment, the three-dimensional structures of
C-CSS2 and C-CSGlcAT, respectively, were modeled using FAMS.
 |
RESULTS
|
|---|
Molecular Cloning of CSS2 and Determination of Its Nucleotide and Amino
Acid SequencesWe performed a BLAST search of the EST data bases
using the amino acid sequence of the cloned human CSGlcAT as a query, and we
found a novel EST (GenBankTM accession number NM_018590
[GenBank]
)
(28). As the sequence was
incomplete, a GeneScan search was performed of human genomic data bases. The
predicted sequence was confirmed by PCR with two primers,
5'-ACTCCTCTGGCTGCTCTGGGGGTTCG-3' and
5'-TCTGGTTTTGGGGGAGAAGTGG-3' (GenBankTM accession number
AB086063
[GenBank]
). The putative amino acid sequences are shown in
Fig. 1A. They
contained an open reading frame of 2328 bp, 775 amino acids, encoding a
typical type II membrane protein with three possible N-glycosylation
sites.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 1. Multiple alignment and genomic structure of CSS2 and CSGlcAT.
A, the multiple alignment of two enzymes was performed using GENETYX.
Introduced gaps are shown with hyphens. The putative transmembrane
domains are underlined. DXD motifs are in boldface.
The 3-glycosyltransferase motif is boxed. Identical amino acids
are shown by asterisks. The possible N-glycosylation sites
are indicated by arrowheads. B, the genome structure of the
CSS2 (top) and CSGlcAT (bottom) genes were
determined by comparing their genomic DNA (GenBankTM accession numbers
NT_005403
[GenBank]
.10 and NT_019447, respectively) and cDNAs. Exon regions are denoted
by boxes. The translation initiation (ATG) and termination (TGA or
TAG) codons are also shown. Black horizontal bars denote the
introns.
|
|
Comparison of Amino Acid Sequences between CSS2 and
CSGlcATThe amino acid sequence of the clone exhibited high
homology (57%) with CSGlcAT in the putative domain as shown in
Fig. 1A. Hydropathy
plots of the amino acid sequence revealed one hydrophobic stretch, located at
position 13-32, like in CSGlcAT (Fig.
1A, underlined). A DXD motif, which is
conserved in many glycosyltransferases and functions as a key sequence for
divalent cation binding, and another motif conserved in
1,3-glycosyltransferases ( 3GTs) were found in the N-terminal half
(Fig. 1, boldface and
boxed, respectively). Comparison of the location of cysteine residues
in the predicted protein encoded by CSS2 (11 cysteines) and that of CSGlcAT
(13 cysteines) showed the good conservation of 10 cysteines not only in the
N-terminal half but also in the C-terminal half. Three potential
N-glycosylation sites also appeared to be conserved in both enzymes.
A remarkable difference between the two amino acid sequences was two short
insertion/deletions near both the N and C termini. The N-terminal
insertion/deletion was likely located in the putative stem region of CSS2, and
the second one was located in the Pro-rich region of CSGlcAT near the C
terminus.
Genome Organization and Chromosome LocalizationA comparison
of the cDNA with the genomic sequence on chromosome 2 revealed the
CSS2 gene to consist of at least four exons
(Fig. 1B,
top). Its genomic organization including the exon-intron boundaries
was quite similar to that of the CSGlcAT gene
(Fig. 1B,
bottom), which consists of four discrete exons in the coding region
(28). The CSS2 and
CSGlcAT genes were located on human chromosome 2q36.1. and 7q36,
respectively.
Estimation of the Amount of FLAG Epitope-tagged CSS2
ProteinTo facilitate the functional analysis of the putative
glycosyltransferase, a soluble form of the protein was generated by replacing
the first 96 amino acids of the putative glycosyltransferase with the
preprotrypsin signal sequence and a FLAG tag, as described under
"Experimental Procedures." The soluble putative
glycosyltransferase was expressed in COS-7 cells as a recombinant enzyme fused
with the FLAG tag. The fused enzyme expressed in the medium was adsorbed onto
anti-FLAG M2 antibody-conjugated agarose gel to eliminate endogenous
glycosyltransferases, and the enzyme-bound gels were used for the various
reactions. The amount of FLAG epitope-tagged CSS2 was estimated using FLAG-BAP
as a standard as described previously
(28). The amount of FLAG-BAP
and the densitometric unit obtained by measurement of each band intensity
showed a correlation (R2 = 0.995) and exhibited a standard
curve, as shown in Fig.
2B. The amount of recombinant CSS2 protein was determined
by plotting 10 ng of the FLAG-BAP as 1 unit that was obtained from 5.3 ml of
the pooled medium (Fig.
2C). CSGlcAT was also isolated, and its protein contents
were determined as 1 unit/5.1 ml of the pooled medium (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2. Estimation of the amount of FLAG epitope-tagged CSS2 protein.
A, Western blot analyses of FLAG-tagged BAP protein and FLAG-tagged
CSS2 protein isolated from serial dilutions of culture medium of COS-7
transfectants stably expressing FLAG-tagged CSS2 protein. The intensity of the
49-kDa (BAP protein) and 90-kDa (CSS2 protein) bands increased with increasing
concentrations of FLAG-tagged BAP protein and the volume of the medium,
respectively. B, depiction of the relationship between the content of
BAP protein and the band density; a linear correlation was noted
(R2 = 0.995). C, depiction of the relationship
between the volume of the medium and the concentration of CSS2 protein, as
derived from the BAP standard curve; a linear correlation was also observed
(R2 = 0.992). The amount of recombinant soluble CSS2
protein is expressed in arbitrary units of intensity each equivalent to 10 ng
of FLAG-tagged BAP protein.
|
|
Acceptor Substrate Specificity of CSS2The acceptor
specificity of the truncated CSS2 recovered from COS-7 transfectant cells was
determined with a variety of glycosaminoglycans and their oligosaccharides as
acceptor substrates. In preliminary experiments, this glycosyltransferase
showed dual enzymatic activities, glucuronyltransferase (GlcAT-II) activity
for CS-C11 and N-acetylgalactosaminyltransferase (GalNAcT-II)
activity for CS-C10 (data not shown). Therefore, we examined the effect of
buffers and pH on both activities of this recombinant glycosyltransferase. As
shown in Fig. 3, the
glycosyltransferase exhibited optimum activity at pH 6.2 and pH 6.5, depending
upon the buffers used, with the highest level in a 50 mM
imidazole-HCl buffer at pH 6.5 for GlcAT-II activity and at pH 6.2 in a 50
mM MES buffer for GalNAcT-II. CSGlcAT exhibited optimum activity at
pH 6.2 in a 50 mM MES buffer for GlcAT-II, but no GalNAcT-II
activity was observed under any pH conditions examined (data not shown). Thus,
all enzymatic reactions were carried out in 50 mM MES buffer, pH
6.2.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 3. Effects of buffers and pH on the GlcAT-II (A) and GalNAcT-II
(B) activities of CSS2. The effects of pH on the GlcUA and GalNAc
transfers to CS-C11 and CS-C10, respectively, were determined under standard
assay conditions with different buffers at a final concentration of 50
mM. The buffers are sodium acetate (open circles),
MES-NaOH (closed circles), imidazole-HCl (open triangles),
and Tris-HCl (closed triangles). Data represent the average of two
independent experiments.
|
|
Divalent cations were essential for the two enzymatic reactions, and 10
mM EDTA completely abolished both activities
(Fig. 4A).
Mn2+ evoked the highest level of activity under standard
assay conditions, and Co2+ was 17 and 31% as effective
as Mn2+ for GlcAT-II and GalNAcT-II activity,
respectively (Fig.
4A). The optimal concentration of
Mn2+ was 10 mM for both activities
(Fig. 4B). In
contrast, Mn2+ only induced activity for GlcAT-II at the
optimal concentration, 15 mM, and no activity was observed with any
other divalent cations examined (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4. Effects of divalent cations (A) and Mn2+
concentration (B) on the GlcAT-II and GalNAcT-II activities.
A, the effects of divalent cations on the GlcUA transfer to CS-C11
(black boxes) and GalNAc transfer to CS-C10 (open boxes)
were determined under standard assay conditions with divalent cations or EDTA
at a final concentration of 10 mM. B, the effects of
Mn2+ concentrations on the GlcUA transfer to CS-C11
(closed circles) and GalNAc transfer to CS-C10 (open
circles) were determined under standard assay conditions, except that the
concentration of MnCl2 was varied. Data represent the average of
two independent experiments.
|
|
The specificity of the recombinant CSS2 toward the UDP-sugar donor
substrate was analyzed using a series of analogs of radiolabeled UDP-GlcUA,
UDP-Gal, UDP-GalNAc, and UDP-GlcNAc under optimized conditions. CSS2 was able
to efficiently catalyze the transfer of GlcUA from UDP-GlcUA to the acceptor
CS-C11 and of GalNAc from UDP-GalNAc to the acceptor CS-C10. In contrast, the
other radiolabeled nucleotide sugars tested (UDP-Gal, UDP-GalNAc, and
UDP-GlcNAc for CS-C11; UDP-GlcUA, UDP-Gal, and UDP-GlcNAc for CS-C10) were not
substrates of the recombinant CSS2 (data not shown). Furthermore, various
monosaccharides including GlcUA -O-4-nitrophenyl,
GlcNAc -O-benzyl, GlcNAc -O-benzyl,
Gal -O-benzyl, Gal -O-benzyl,
GalNAc -O-benzyl, and GalNAc -O-benzyl were not
efficient acceptor substrates for any of the UDP-sugars tested as donors (data
not shown).
To characterize the substrate specificity of the purified recombinant CSS2,
chondroitin, chondroitin sulfate isoforms, and other glycosaminoglycans were
tested as acceptor substrates. As shown in
Table I, chondroitin was the
best substrate, and the other polymer chondroitin sulfate isoforms were poor
acceptors for both enzyme activities of CSS2, as well as the GlcAT-II activity
of CSGlcAT.
As shown in Table I, CSS2
apparently showed GlcAT-II activity toward undecasaccharides having GalNAc in
their non-reducing termini, which were prepared from the CS isoforms and
chondroitin. The activities for the CS-A and CS-C undecasaccharides were 2.7-
and 4.5-fold higher than the activity for the chondroitin undecasaccharide,
respectively, and the activity for the hyaluronan undecasaccharide was
negative. On the other hand, CSS2 apparently showed GalNAcT-II activity toward
decasaccharides having GlcUA at their non-reducing termini, which were
prepared from CS isoforms and chondroitin. The activities for both CS-A and
CS-C decasaccharides were 3.1-fold higher than that for the chondroitin
decasaccharide, and the activity was negative for hyaluronan decasaccharide.
To examine whether CSS2 has other glycosyltransferase activities, several
substrates,
Gal 13Gal 14Xyl 1-O-methoxyphenyl
and
GlcUA 13Gal 13Gal 14Xyl 1-O-methoxyphenyl
(GlcAT-I and GalNAcT-I for glycosaminoglycan linkage region, respectively)
(Table I),
Gal 13GalNAc -O-benzyl (human natural killer cell-1
epitope synthase) and
Gal 14GlcNAc 13Gal 14GlcNAc (lactosamine
tetrasaccharide) (data not shown), were tested as acceptors, but no activity
was detected. These results again suggested that CSS2 is responsible for the
chondroitin sulfate elongation and not for the linkage tetrasaccharide or
other substrates.
Effects of the acceptor length of oligosaccharides on CSS2 activities were
determined using CS-C and chondroitin oligosaccharides
(Fig. 5). The odd-numbered
oligosaccharides from CS-C and chondroitin having a GalNAc residue in the
non-reducing terminus were subjected to an assay for GlcAT-II activity. The
even-numbered oligosaccharides having a GlcUA residue in the non-reducing
terminus were subjected to a GalNAcT-II assay. CSS2 exhibited GlcAT-II
activity toward the odd-numbered oligosaccharides from CS-C and chondroitin
and GalNAcT-II activity toward the even-numbered oligosaccharides. For the
GlcAT-II activity, the longer oligosaccharides served as better acceptors than
the shorter ones. On the other hand, for the GalNAcT-II activity, CSS2
transferred GalNAc most efficiently to CS-C10 among the CS-C or chondroitin
oligosaccharides examined (Fig.
5). For both the GlcAT-II and the GalNAcT-II activity, the CS-C
oligosaccharides were better acceptor substrates than the chondroitin
oligosaccharides, especially for the GalNAcT-II activity, the former acceptor
activities being 2.8- and 4.8-fold higher than the latter for deca- and
octasaccharides, respectively (Fig.
5).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 5. Influence of chain length of acceptor substrate on GlcAT-II (A)
and GalNAcT-II activities (B) of CSS2. Odd-numbered CS-C (A,
open circles) or chondroitin (A, closed circles)
oligosaccharides with terminal non-reducing N-acetylgalactosaminyl
residues and even numbered CS-C (B, open circles) or chondroitin
(B, closed circles) were used as acceptor substrates at a final
concentration of 33 mM. Data represent the average of two
independent experiments.
|
|
Analysis of CSS2 Reaction ProductsTo identify the GlcAT-II
reaction products, chondroitin polymer was labeled with
[14C]UDP-GlcUA by CSS2 under optimized conditions, and the products
were isolated and then subjected to a gel filtration analysis after
chondroitinase AC-II or -glucuronidase treatment. As shown in
Fig. 6A, the labeled
products were completely digested by chondroitinase AC-II and
-glucuronidase, quantitatively yielding a 14C-labeled peak at
the position of [14C]GlcUA 13GalNAc and of free
[14C]GlcUA, respectively. These findings indicate that a GlcUA
residue was transferred to the non-reducing terminal GalNAc residue of
chondroitin polymer through a -linkage. Furthermore,
14C-labeled chondroitin sulfate dodecasaccharide was used as an
acceptor for a chondroitin polymerase from an E. coli K4 strain
(31). This reaction was
performed in the presence of the enzyme and two donor substrates, UDP-GalNAc
and UDP-GlcUA. The reaction products showed a molecular mass of 3000 Da
that was speculated to be the product transferred by 5 sugar residues.
They were digested by chondroitinase AC-II, yielding unsaturated
GlcUA 13GalNAc disaccharides. These results indicated the
[14C]GlcUA transferred by CSS2 at the non-reducing terminal of
CS-C11 could serve as a substrate for E. coli K4 chondroitin
polymerase, and the resultant internal [14C]GlcUA residue linked by
a -linkage to GalNAc was susceptible to chondroitinase AC-II digestion.
These findings strongly suggested that a GlcUA residue was transferred to the
non-reducing terminal GalNAc residue of chondroitin sulfate undecasaccharides
through a 13-linkage.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6. Identification of the putative human glycosyltransferase reaction
products. A, the GlcAT-II reaction products with polymer
chondroitin recovered from a Superdex Peptide column were digested with
chondroitinase AC-II or -glucuronidase as described under
"Experimental Procedures." The non-digested sample (open
circles), the chondroitinase AC-II digest (closed circles), or
the -glucuronidase digest (closed triangles) was applied to a
column of Superdex Peptide, and the respective fractions (0.5 ml each) were
analyzed for radioactivity. Arrows indicate the elution positions of
the authentic saturated disaccharide (closed arrowhead,
GlcUA 13GalNAc) or free GlcUA (open arrowhead).
B, the GlcAT-II reaction products with CS11 recovered from a Superdex
Peptide column were subjected to chondroitin polymerization with E.
coli strain K4 chondroitin polymerase or chondroitinase AC-II digestion
of the resultant polymer as described under "Experimental
Procedures." The [14C]GlcUA-labeled CS-C11 oligosaccharide
sample (open circles), the sample polymerized by E. coli
strain K4 chondroitin polymerase (closed circles), or the
chondroitinase AC-II digest of the E. coli strain K4 chondroitin
polymerase products (closed triangles) was applied to a column of
Superdex Peptide, and the respective effluent fractions (0.5 ml each) were
analyzed for radioactivity. Arrows indicate the elution positions of
the authentic saturated disaccharide (closed arrowhead,
GlcUA 13GalNAc). C, the GalNAcT-II reaction products with
polymer chondroitin recovered from a Superdex Peptide column were subjected to
digestion with chondroitinase AC-II or
-N-acetylgalactosaminidase as described under
"Experimental Procedures." The undigested sample (open
circles), the chondroitinase AC-II digest (filled circles), or
the -N-acetylgalactosaminidase digest (filled
triangles) was applied to a column of Superdex Peptide, and the
respective fractions (0.5 ml each) were analyzed for radioactivity.
Arrows indicate the elution positions of the authentic free GalNAc
(open arrowhead).
|
|
To identify the GalNAcT-II reaction products, chondroitin polymer was
labeled with [3H]GalNAc by CSS2, and the products were isolated and
then subjected to a gel filtration analysis after chondroitinase AC-II
treatment. As shown in Fig.
6C, the labeled products were completely digested by
chondroitinase AC-II, quantitatively yielding a 3H-labeled peak at
the position of free [3H]GalNAc, which was separable from
GlcUA 13GalNAc. In addition, they were inert to the action of
-N-acetylgalactosaminidase. These findings clearly indicated
that a GalNAc residue had been transferred exclusively to the non-reducing
terminal GlcUA residue of polymer chondroitin through a
14-linkage. Together with the above results they suggested that
the identified protein is chondroitin synthase with both CSGlcAT-II and
CSGalNAcT-II activity.
Kinetic Analysis of CSS2We investigated the effect of the
concentrations of the donor substrates, UDP-GlcUA and UDP-GalNAc, and the
acceptor substrates, CS-C11 and CS-C10, on the activities of CSS2. As shown in
Fig. 7, the apparent
Km values for UDP-GlcUA and CS-C11 for GlcAT
activity were 263 µM (R2 = 0.996) and 27
µM (R2 = 0.992), respectively. The apparent
Km values for UDP-GalNAc and CS-C10 for GalNAc-T
activity were 670 µM (R2 = 0.999) and 22
µM (R2 = 0.997), respectively.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 7. Effects of the concentration of UDP-sugars (A) and CS
oligosaccharides (B) on the activity of CSS2. A, the
kinetic behaviors of CSS2 regarding UDP-GlcUA to CS-C11 (closed
circles) and UDP-GalNAc to CS-C10 (open circles). B,
the kinetic behaviors of CSS2 regarding CS-C11 to UDP-GlcUA (closed
circles) and CS-C10 to UDP-GalNAc (open circles). UDP-sugars and
CS-C oligosaccharides were added to the established assay mixture at different
final concentrations as described under "Experimental Procedures."
Data represent the average of two independent experiments.
|
|
Quantitative Analysis of the CSGlcAT Transcript in Human Tissues by
Real Time PCRThe tissue distribution and the expression levels of
the CSS2 transcripts were also investigated in comparison with those of the
CSS1 and CSGlcAT transcripts, by the real time PCR method. Expression levels
of CSS2, CSGlcAT, and CSS1 in various tissues are shown as the relative amount
versus the GAPDH transcripts in
Fig. 8. All the enzymes were
expressed ubiquitously, but with some difference, in all tissues examined.
Notably, the expression of CSS2 was particularly abundant in pancreas, ovary,
placenta, small intestine, and stomach. These ubiquitous expression patterns
of the enzyme are consistent with the broad distribution of CS proteoglycans
throughout the body.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 8. Quantitative analysis of CSGlcAT and CSSs transcripts in human tissues
by real time PCR. Standard curves for CSS2, CSS1, CSGlcAT, and GAPDH were
generated by serial dilution of each plasmid DNA. The expression levels of the
CSS2 (closed bars), CSS1 (open bars), and CSGlcAT
(slashed bars) transcripts were normalized to those of the GAPDH
transcripts which were measured using the same cDNAs. Data were obtained from
triplicate experiments and are indicated as the mean ± S.D.
|
|
Multiple Alignments and Molecular Modeling of C-terminal Halves of
Bovine 4-Galactosyltransferase and Human Chondroitin
GlycosyltransferasesAlthough CSS2 and CSGlcAT are highly
homologous, CSS2 exhibits GalNAcT-II activity, whereas CSGlcAT does not. To
address the regions that contribute to the GalNAcT-II activity, we elaborated
a multiple alignment of the CS glycosyltransferases.
Fig. 9 shows the alignment of
bovine 4-galactosyltransferase ( 4Gal-T1; Protein Data Bank code
1FR8A) and C-CSS1 by 3D-PSSM, a threading method, combined with multiple
alignments of C-CSS1, CSGalNAcT-1, CSGalNAcT-2, C-CSS2, and C-CSGlcAT. The
comparison of elements of secondary structure of 4Gal-T1 by
crystallography and C-CSGlcAT by PSIPRED2 prediction aligned with other CS
glycosyltransferases indicated that these molecules were basically constructed
within the similar molecular architecture
(Fig. 9). Interestingly, by the
structure-based multiple alignment, the second aspartic acid residue of the
DXD motif, which is conserved in 4Gal-T1, C-CSS1, CSGalNAcT-1,
and CSGalNAcT-2, was shown to be conserved at Asp617 in CSS2 but
not in CSGlcAT (Fig. 9, 1st
small half-box). Furthermore, this alignment showed that two regions in
C-CSS2 and C-CSGlcAT were unable to be constructed in their three-dimensional
structure models because they were extra regions compared with 4Gal-T1
(Fig. 9, black and
red boxes). One is the 33 and 32 amino acid residues in N-terminal
region of C-CSS2 and C-CSGlcAT, respectively
(Fig. 9, black box).
Another is 17 and 33 amino acid residues between the regions corresponding to
the DXD motif and 4Gal-T1 motif (GWGGEDDD) in C-CSS2 and
C-CSGlcAT, respectively (Fig.
9, red box).

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 9. Multiple alignment of 4GalT-1 and C-CSS1, CSGalNAcT-1,
CSGalNAcT-2, C-CSS2, and C-CSGlcAT. The alignment of C-CSS1 with bovine
4-galactosyltransferase (Protein Data Bank code 1FR8A) by 3D-PSSM and
the alignment of C-CSS1 with CSGalNAc-T1, CSGalNAcT2, C-CSS2, and C-CSGlcAT
using ClustalW were aligned together along the C-CSS1 sequence. Amino acids
are divided into five groups as follows: D, E, N, Q as group 1; H, K, R as
group 2; F, W, Y as group 3; C, I, L, M, V as group 4; and A, G, P, S, T as
group 5. The sites where at least two-thirds amino acids are within a group
are colored red, blue, orange, yellow, and green for the
groups 15, respectively. Elements of the secondary structure are
depicted above the sequences for 4Gal-T1 based on
crystallography and below the sequences for C-CSGlcAT based on the
PSIPRED2 prediction; e, -strand; h, -helix.
Black half-boxes above the sequences show the putative DXD
motif (1st small half-box) and 4 glycosyltransferase motif
(GWGGEDDD, 2nd large half-box). Black and red boxes
in C-CCS2 and C-CSGlcAT sequences indicate the regions that were unable to be
constructed in their three-dimensional structural models because these were
extra regions compared with 4Gal-T1.
|
|
We then performed the molecular modeling of the C-terminal half of these
two enzymes. A comparison of the three-dimensional structural models of C-CSS2
and C-CSGlcAT revealed that the latter region, 17 and 33 amino acid residues
in C-CSS2 and C-CSGlcAT, respectively (Fig.
9, red box), were located near the predicted catalytic
sites of each enzyme (Fig. 10,
dotted line in the left of the models). The three-dimensional
structure of these regions could not been constructed, because these regions
were lacked in 4Gal-T1 as a template for three-dimensional modeling.
Therefore, if they may form loop structure and have a similar orientation in
each molecule, the long loop (33 amino acid residues) in CSGlcAT may influence
the catalytic reaction of this enzyme and the shorter (17 amino acid residues)
loop in C-CSS2 may not. Therefore, we concluded that this result is the one of
possible reasons in the difference of GalNAcT-II activity between CSS2 and
CSGlcAT.
 |
DISCUSSION
|
|---|
In this report, we have described the cloning and characterization of a
novel human chondroitin sulfate synthase (CSS2) based on homology with human
CSGlcAT (28), which exhibits
both glucuronyltransferase II (GlcAT-II) and
N-acetylgalactosaminyltransferase II (GalNAcT-II) activity for CS
chain elongation in vitro. This enzyme is the fifth CS
glycosyltransferase. The presence of at least five distinct enzymes involved
in CS initiation and elongation suggests that CS synthesis takes place via a
similar mechanism to heparan sulfate synthesis where five homologous EXT
family members with distinct, but overlapping, acceptor specificities are
involved (29).
In this study we first expressed and purified CSS2 and CSGlcAT as soluble
enzymes, and we investigated the properties of purified CSS2 compared with
CSGlcAT. Surprisingly, CSS2 exhibited not only GlcAT-II activity but also
GalNAcT-II activity which CSGlcAT lacked, although these two enzymes exhibited
high homology. Characterization of CSS2 revealed an Mn2+
requirement (10 mM) for maximal activity and a pH optimum of 6.5
and 6.2 for GlcAT-II activity and GalNAcT-II activity, respectively. On the
other hand, CSGlcAT revealed an Mn2+ requirement (15
mM) for maximal activity and pH optimum of 6.2 for GlcAT-II
activity (data not shown). Under optimal conditions, the substrate specificity
of CSS2 was shown to be similar to that of CSS1 and CSGlcAT for GlcAT-II
activity and of CSS1 for GalNAcT-II activity. In summary, all of the three
enzymes prefer the nonsulfated isomer as a polymer substrate and sulfated
isomer as oligosaccharide substrates
(23,
28), and the same
specificities were also observed in CSGalNAcT-1
(26), CSGalNAcT-2
(25), bovine serum
-glucuronyltransferase, and bovine serum
N-acetylgalactosaminyltransferase
(37,
38). Sulfation of CS
ordinarily proceeds together with polymerization at the Golgi apparatus, and
specific sulfate groups have either stimulatory or inhibitory effects on
GalNAc and GlcUA transfer
(3739).
Furthermore, earlier studies have suggested that 4,6-O-sulfation of
GalNAc (40,
41) or 3-O-sulfation
of GlcUA (42) residues at the
non-reducing end might be involved in CS chain termination. Therefore, the
specificities observed in the cloned CS glycosyltransferases in vitro
suggested that the sulfate transfer may coincide with the CS
glycosyltransferase reaction to the growing chondroitin sulfate chain and
plays important roles in chain elongation and termination.
The Km values of CSS2 for UDP-GlcUA and
UDP-GalNAc were relatively high (263 and 670 µM, respectively)
compared with the values of CSGlcAT (82 µM for UDP-GlcUA),
bovine serum -glucuronyltransferase (50 µM for UDP-GlcUA),
and bovine serum N-acetylgalactosaminyltransferase (50
µM for UDP-GalNAc)
(37,
38), although in the studies
of serum enzymes chondroitin polymer was used as an acceptor instead of
chondroitin sulfate oligosaccharides. Sasai et al.
(43) showed that human
1,6-N-acetylglucosaminyltransferase V (GnT-V) exhibited an
exceptionally higher Km value (4 mM)
for the UDP-GlcNAc donor nucleotide sugar than other GlcNAc transferases. They
proposed that the production of 1,6-branched oligosaccharide, which is
formed by GnT-V, could be regulated in vivo by the concentration of
the donor, UDP-GlcNAc, as well as the expression levels of the enzyme
(43). The differences in
Km values of each chondroitin sulfate
glycosyltransferases for donor substrates may be one of the factors regulating
the biosynthetic machinery of CS chains.
The primary structure of CSS2 was highly conserved with that of CSGlcAT
(57% identity) (Fig. 1).
Several motifs observed in many glycosyltransferases, most of the cysteine
residues, and all of the N-glycosylation potential sites were well
conserved in both enzymes, suggesting that their overall molecular structure
should be very similar. However, CSGlcAT lacks GalNAcT-II activity, whereas
CSS2 has this activity. Many glycosyltransferases have been shown to contain a
DXD motif, critical for catalytic function
(44). The DXD motif
may be essential for binding the UDP-sugar donor through the coordination of a
divalent cation (45). In the
predicted catalytic domain for GalNAcT-II activity in CSS2, which is supposed
to be in the C-terminal half of this enzyme, the typical DXD motif is
absent, and the amino acid sequence in the corresponding domain is different
from that of CSGlcAT (Fig.
1A). In the C-terminal half of CSS2, we found a
GPD617 sequence, aligned with the DVD sequence in 4Gal-T1 and
in the putative GalNAcT domains of the other chondroitin glycosyltransferases,
CSS1, GSCalNAcT-1, and CSGalNAcT-2, by multiple alignment
(Fig. 9). Interestingly, this
aspartic acid residue is not conserved in CSGlcAT lacking GalNAcT-II activity
(Fig. 9). Although the
canonical DXD motif contains two aspartic acid residues, the first
(in the 1st position of the motif) is relatively variable, and the second (in
the 3rd position of the motif) is quite well conserved
(46). By analyses of the
crystal structure of human 1,3-glucuronyltransferase I (GlcAT-I)
(45) and bovine
1,4-galactosyltransferase ( 4Gal-T1)
(44) in the presence of the
donor substrate product UDP, the catalytic Mn2+ ion, and
the acceptor substrate, their conserved DXD motifs were shown to
directly interact with the Mn2+ ion. In both cases, the
second aspartic acid residue in the DXD sequence is important for
coordination with the Mn2+ ion
(44,
45). Furthermore, in rabbit
N-acetylglucosaminyltransferase I, the DXD motif is present
in the form 211EDD213, in which the 3rd position
Asp213 makes the only direct interaction with the bound
Mn2+ ion and is essential for enzyme activity
(46). These results indicate
that the second aspartic acid residue in the DXD motif may be
necessary and adequate for metal ion binding and that the Asp617
residue of GPD617 in CSS2, which is absent in CSGlcAT, may be
adequate for its GalNAcT-II activity. However, the other motif, the
DXH motif, is also found in some other glycosyltransferases including
polypeptide GalNAc transferases classified as GT-27 or GT-60 in the CAZy data
base, which may be essential for its metal ion-dependent glycosyltransferase
activities (47). Therefore, it
is still difficult to anticipate the GalNAcT-II active site from the homology
of the primary amino acid sequence of CSS2 with other
4-glycosyltransferases.
The other remarkable difference in the amino acid sequences of the two
enzymes, CSS2 and CSGlcAT, is two short insertions (see
Fig. 1) from other chondroitin
glycosyltransferases, such as CSS1, CSGalNAc-T1, and CSGalNAc-T2 (data not
shown). The former insertion, in the stem region of CSS2, may alter its
localization in the Golgi membrane or the interaction with other molecules
(36), whereas the latter may
influence the catalytic function of CSGlcAT. Actually, our molecular modeling
suggests that this insertion is located near the predicted catalytic domain of
C-CSGlcAT, which aligned with the putative GalNAcT domains of 4Gal-T1
and the other CS glycosyltransferases
(Fig. 10C). In this
insertion, which contains many proline and glycine residues, secondary
structures were not predicted (Fig.
9). The longer amino acid loop may interfere with the binding of
UDP-GalNAc or acceptor substrates to the catalytic domain.
The genomic organization of both of the cloned chondroitin
glycosyltransferases involved in chondroitin backbone formation has been
shown. The open reading frames of the human CSS2 and CSGlcAT
genes are distributed among four exons that span 4.1 and 4.7 kb,
respectively. Comparison of the genomic organization of these two genes shows
a quite similar genetic exon-intron organization within the coding sequence
(Fig. 1) as described in the
case of CSGalNAcT-1 and CSGalNAcT-2
(24). Interestingly,
chromosomal assignments of the five human chondroitin glycosyltransferases,
CSS1, CSS2, CSGlcAT, CSGalNAcT-1, and CSGalNAcT-2, indicate
that these genes are localized on different chromosomes, at 15q26.3, 2q36.1,
7q36, 8q21.3, and 10q11.22, respectively, despite significant homology in the
nucleotide and amino acid sequences of the five genes
(2327).
Furthermore, recently we found CSS3, which is homologous to CSS1, the same as
CSS2 for CSGlcAT and CSGalNAcT-2 for
CSGalNAcT-1.2 These
findings suggest that chondroitin glycosyltransferases can be classified into
three pairs: CSS1/CSS3, CSS2/CSGlcAT, and CSGalNAcT-2/CSGalNAcT-1. During
evolution, an ancestor gene might have diverged into three genes, and each of
them underwent duplication.
The CSS2 gene exhibited ubiquitous but characteristic expression
patterns compared with CSGlcAT. A particularly striking difference is its high
level of expression in the pancreas and ovary and moderate levels in the
placenta, stomach, and small intestine
(Fig. 8). In contrast, CSGlcAT
is highly expressed in the placenta, followed by the small intestine and
pancreas, similar to the pattern of CSS1 expression
(Fig. 8)
(28). Therefore, CSS2 may play
a more unique role in the biosynthesis of chondroitin sulfate than CSGlcAT in
human tissues.
Taken together, at least five enzymes, CSS1, CSS2, CSGalNAcT-1,
CSGalNAcT-2, and CSGlcAT, whose expression patterns in human tissues are
ordinarily similar to each other, may play roles at different stages in the
synthesis of CS in a cooperative or orchestrated manner. The recent cloning,
expression, and characterization of many glycosyltransferases have provided
great progress in understanding chondroitin sulfate biosynthesis. Because none
of these enzymes can form an entire glycosaminoglycan chain, the formation of
a complex as machinery may be required for CS chain elongation in
vitro. To understand the nature of the interactions of these molecules
forming a complex, the various membrane-bound enzymes, appropriate substrates,
and membrane-bound nascent proteoglycans are fundamental for determining the
specificities of structure and efficiency in formation of the CS chain.
 |
FOOTNOTES
|
|---|
The nucleotide sequence(s) reported in this paper has been submitted to
the GenBankTM/EBI Data Bank with accession number(s)
AB086063
[GenBank]
.
* This work was performed as part of the R&D Project of the Industrial
Science and Technology Frontier Program (R&D for the Establishment and
Utilization of a Technical Infrastructure for Japanese Industry) supported by
the New Energy and Industrial Technology Development Organization (NEDO). This
work was also supported by grants-in-aid for Scientific Research on Priority
Areas (C) "Genome Information Science" and for Scientific Research
(B) (to M. G.) and by the Ministry of Education, Culture, Sports, Science and
Technology of Japan. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be hereby
marked "advertisement" in accordance with 18 U.S.C.
Section 1734 solely to indicate this fact. 
¶ Both authors contributed equally to this work as first authors. 
||||
To whom correspondence should be addressed: Institute for Molecular Science of
Medicine, Aichi Medical University, Yazako, Nagakute, Aichi 480-1195, Japan.
Tel.: 81-561-62-3311; Fax: 81-561-63-3532; E-mail:
kimata{at}aichi-med-u.ac.jp.
1 The abbreviations used are: CS, chondroitin sulfate; ( 3)GlcAT,
( 1,3)-glucuronyltransferase; ( 3 or 4)-Gal-T, ( 1,3 or
1,4)-galactosyltransferase; ( 4)GalNAc-T,
( 1,4)-N-acetylgalactosaminyltransferase; EST, expressed
sequence tag; GAPDH, glyceraldehydes-3-phosphate dehydrogenase; MES,
2-(N-morpholino)ethanesulfonic acid. 
2 T. Yada, T. Sato, H. Kaseyama, M. Gotoh, H. Iwasaki, N. Kikuchi, Y. D.
Kwon, A. Togayachi, T. Kudo, H. Watanabe, H. Narimatsu, and K. Kimata,
unpublished observations. 
 |
ACKNOWLEDGMENTS
|
|---|
We thank Seikagaku Corp. for providing the substrates and the enzymes. We
also thank Drs. T. Ninomiya and N. Sugiura for E. coli strain K4
chondroitin polymerase.
 |
REFERENCES
|
|---|
- Schwartz, N. B., and Domowicz, M. (2002)
Glycobiology 12,
57R68R[Abstract/Free Full Text]
- Bandtlow, C. E., and Zimmermann, D. R. (2000)
Physiol. Rev. 80,
12671290[Abstract/Free Full Text]
- Kimata, K., Okayama, M., Ooira, A., and Suzuki, S.
(1973) Mol. Cell. Biochem.
1,
211228[CrossRef][Medline]
[Order article via Infotrieve]
- Silbert, J. E., and Sugumaran, G. (2002)
IUBMB Life 54,
177186[Medline]
[Order article via Infotrieve]
- Vertel, B. M., Walters, L. M., Flay, N., Kearns, A. E., and
Schwartz, N. B. J. Biol. Chem.
268, 111051111,
1993[Abstract/Free Full Text]
- Inoue, H., Otsu, K., Yoneda, M., Kimata, K., Suzuki, S., and
Nakanishi, Y. (1986) J. Biol. Chem.
261,
44604469[Abstract/Free Full Text]
- Gotting, C., Kuhn, J., Zahn, R., Brinkmann, T., and Kleesiek, K.
(2000) J. Mol. Biol.
304,
517528[CrossRef][Medline]
[Order article via Infotrieve]
- Almeida, R., Levery, S. B., Mandel, U., Kresse, H., Schwientek, T.,
Bennett, E. P., and Clausen, H. (1999) J. Biol.
Chem. 274,
2616526171[Abstract/Free Full Text]
- Okajima, T., Yoshida, K., Kondo, T., and Furukawa, K.
(1999) J. Biol. Chem.
274,
2291522918[Abstract/Free Full Text]
- Bai, X., Zhou, D., Brown, J. R., Crawford, B. E., Hennet, T., and
Esko, J. D. (2001) J. Biol. Chem.
276,
4818948195[Abstract/Free Full Text]
- Kitagawa, H., Tone, Y., Tamura, J., Neumann, K. W., Ogawa, T., Oka,
S., Kawasaki, T., and Sugahara, K. (1998) J. Biol.
Chem. 273,
66156618[Abstract/Free Full Text]
- Wei, G., Bai, X., Sarkar, A. K., and Esko, J. D.
(1999) J. Biol. Chem.
274,
78577864[Abstract/Free Full Text]
- Maimone, M. M., and Tollefsen, D. M. (1990)
J. Biol. Chem. 265,
1826318271[Abstract/Free Full Text]
- Lyon, M., Deakin, J. A., Rahmoune, H., Fernig, D. G., Nakamura, T.,
and Gallagher, J. T. (1998) J. Biol.
Chem. 273,
271278[Abstract/Free Full Text]
- Razin, E., Stevens, R. L., Akiyama, F., Schmid, K., and Austen, K.
F. (1982) J. Biol. Chem.
257,
72297236[Abstract/Free Full Text]
- Maeda, N., Ichihara-Tanaka, K., Kimura, T., Kadomatsu, K.,
Muramatsu, T., and Noda, M. (1999) J. Biol.
Chem. 274,
1247412479[Abstract/Free Full Text]
- Naujokas, M. F., Morin, M., Anderson, M. S., Peterson, M., and
Miller, J. (1993) Cell
74,
257268[CrossRef][Medline]
[Order article via Infotrieve]
- Fried, M., and Duffy, P. E. (1996)
Science 272,
15021504[Abstract]
- Yamauchi, S., Mita, S., Matsubara, T., Fukuta, M., Habuchi, H.,
Kimata, K., and Habuchi, O. (2000) J. Biol.
Chem. 275,
89758981[Abstract/Free Full Text]
- Uchimura, K., Muramatsu, H., Kadomatsu, K., Fan, Q. W., Kurosawa,
N., Mitsuoka, C., Kannagi, R., Habuchi, O., and Muramatsu, T.
(1998) J. Biol. Chem.
273,
2257722583[Abstract/Free Full Text]
- Kobayashi, M., Sugumaran, G., Liu, J., Shworak, N. W., Silbert, J.
E., and Rosenberg, R. D. (1999) J. Biol.
Chem. 274,
1047410480[Abstract/Free Full Text]
- Ohtake, S., Ito, Y., Fukuta, M., and Habuchi, O.
(2001) J. Biol. Chem.
276,
4389443900[Abstract/Free Full Text]
- Kitagawa, H., Uyama, T., and Sugahara, K. (2001)
J. Biol. Chem. 276,
3872138726[Abstract/Free Full Text]
- Uyama, T., Kitagawa, H., Tanaka, J., Tamura, J. I., Ogawa, T., and
Sugahara, K. (2002) J. Biol. Chem.
278,
30723078[Medline]
[Order article via Infotrieve]
- Sato, T., Gotoh, M., Kiyohara, K., Akashima, T., Iwasaki, H.,
Kameyama, A., Mochizuki, H., Yada, T., Inaba, N., Togayachi, A., Kudo, T.,
Asada, M., Watanabe, H., Imamura, T., Kimata, K., and Narimatsu, H.
(2002) J. Biol. Chem.
278,
30633071[Medline]
[Order article via Infotrieve]
- Gotoh, M., Sato, T., Akashima, T., Iwasaki, H., Kameyama, A.,
Mochizuki, H., Yada, T., Inaba, N., Zhang, Y., Kikuchi, N., Kwon, Y. D.,
Togayachi, A., Kudo, T., Nishihara, S., Watanabe, H., Kimata, K., and
Narimatsu, H. (2002) J. Biol. Chem.
277,
3818938196[Abstract/Free Full Text]
- Uyama, T., Kitagawa, H., Tamura Ji, J., and Sugahara, K.
(2002) J. Biol. Chem.
277,
88418846[Abstract/Free Full Text]
- Gotoh, M., Yada, T., Sato, T., Akashima, T., Iwasaki, H.,
Mochizuki, H., Inaba, N., Togayachi, A., Kudo, T., Watanabe, H., Kimata, K.,
and Narimatsu, H. (2002) J. Biol. Chem.
277,
3817938188[Abstract/Free Full Text]
- Zak, B. M., Crawford, B. E., and Esko, J. D. (2002)
Biochim. Biophys. Acta
1573,
346355[Medline]
[Order article via Infotrieve]
- Bitter, T., and Muir, H. M. (1962) Anal.
Biochem. 4,
330334[CrossRef][Medline]
[Order article via Infotrieve]
- Ninomiya, T., Sugiura, N., Tawada, A., Sugimoto, K., Watanabe, H.,
and Kimata, K. (2002) J. Biol. Chem.
277,
2156721575[Abstract/Free Full Text]
- Iwai, T., Inaba, N., Naundorf, A., Zhang, Y., Gotoh, M., Iwasaki,
H., Kudo, T., Togayachi, A., Ishizuka, Y., Nakanishi, H., and Narimatsu, H.
(2002) J. Biol. Chem.
277,
1280212809[Abstract/Free Full Text]
- Ogata, K., and Umeyama, H. (2000) J. Mol.
Graphics Model 18,
258272, 305256[CrossRef][Medline]
[Order article via Infotrieve]
- Thompson, J. D., Higgins, D. G., and Gibson, T. J.
(1994) Nucleic Acids Res.
22,
46734680[Abstract/Free Full Text]
- Jones, D. T. (1999) J. Mol.
Biol. 292,
195202[CrossRef][Medline]
[Order article via Infotrieve]
- Sasai, K., Ikeda, Y., Tsuda, T., Ihara, H., Korekane, H., Shiota,
K., and Taniguchi, N. (2001) J. Biol.
Chem. 276,
759765[Abstract/Free Full Text]
- Kitagawa, H., Tsuchida, K., Ujikawa, M., and Sugahara, K.
(1995) J. Biochem. (Tokyo)
117,
10831087[Abstract/Free Full Text]
- Kitagawa, H., Ujikawa, M., Tsutsumi, K., Tamura, J., Neumann, K.
W., Ogawa, T., and Sugahara, K. (1997)
Glycobiology 7,
905911[Abstract/Free Full Text]
- Gundlach, M. W., and Conrad, H. E. (1985)
Biochem. J. 226,
705714[Medline]
[Order article via Infotrieve]
- Inoue, H., Otsu, K., Suzuki, S., and Nakanishi, Y.
(1986) J. Biol. Chem.
261,
44704475[Abstract/Free Full Text]
- Otsu, K., Inoue, H., Tsuzuki, Y., Yonekura, H., Nakanishi, Y., and
Suzuki, S. (1985) Biochem. J.
227,
3748[Medline]
[Order article via Infotrieve]
- Kitagawa, H., Tsutsumi, K., Ujikawa, M., Goto, F., Tamura, J.,
Neumann, K. W., Ogawa, T., and Sugahara, K. (1997)
Glycobiology 7,
531537[Abstract/Free Full Text]
- Sasai, K., Ikeda, Y., Fujii, T., Tsuda, T., and Taniguchi, N.
(2002) Glycobiology
12,
119127[Abstract/Free Full Text]
- Boeggeman, E., and Qasba, P. K. (2002)
Glycobiology 12,
395407[Abstract/Free Full Text]
- Pedersen, L. C., Tsuchida, K., Kitagawa, H., Sugahara, K., Darden,
T. A., and Negishi, M. (2000) J. Biol.
Chem. 275,
3458034585[Abstract/Free Full Text]
- Unligil, U. M., Zhou, S., Yuwaraj, S., Sarkar, M., Schachter, H.,
and Rini, J. M. (2000) EMBO J.
19,
52695280[CrossRef][Medline]
[Order article via Infotrieve]
- Hagen, F. K., Hazes, B., Raffo, R., deSa, D., and Tabak, L. A.
(1999) J. Biol. Chem.
274,
67976803[Abstract/Free Full Text]

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Kampf, B. Absmanner, M. Schwarz, and L. Lehle
Biochemical Characterization and Membrane Topology of Alg2 from Saccharomyces cerevisiae as a Bifunctional {alpha}1,3- and 1,6-Mannosyltransferase Involved in Lipid-linked Oligosaccharide Biosynthesis
J. Biol. Chem.,
May 1, 2009;
284(18):
11900 - 11912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Izumikawa, T. Koike, S. Shiozawa, K. Sugahara, J.-i. Tamura, and H. Kitagawa
Identification of Chondroitin Sulfate Glucuronyltransferase as Chondroitin Synthase-3 Involved in Chondroitin Polymerization: CHONDROITIN POLYMERIZATION IS ACHIEVED BY MULTIPLE ENZYME COMPLEXES CONSISTING OF CHONDROITIN SYNTHASE FAMILY MEMBERS
J. Biol. Chem.,
April 25, 2008;
283(17):
11396 - 11406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Borg and M. Holland
The effect of glycosaminoglycans on rat gametes in vitro and the associated signal pathway
Reproduction,
March 1, 2008;
135(3):
311 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Dick, F. Grondahl, and K. Prydz
Overexpression of the 3'-Phosphoadenosine 5'-Phosphosulfate (PAPS) Transporter 1 Increases Sulfation of Chondroitin Sulfate in the Apical Pathway of MDCK II Cells
Glycobiology,
January 1, 2008;
18(1):
53 - 65.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakai, K. Kimata, T. Sato, M. Gotoh, H. Narimatsu, K. Shinomiya, and H. Watanabe
Chondroitin Sulfate N-Acetylgalactosaminyltransferase-1 Plays a Critical Role in Chondroitin Sulfate Synthesis in Cartilage
J. Biol. Chem.,
February 9, 2007;
282(6):
4152 - 4161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Sato, M. Sato, K. Kiyohara, M. Sogabe, T. Shikanai, N. Kikuchi, A. Togayachi, H. Ishida, H. Ito, A. Kameyama, et al.
Molecular cloning and characterization of a novel human {beta}1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain
Glycobiology,
December 1, 2006;
16(12):
1194 - 1206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ikehara, T. Sato, T. Niwa, S. Nakamura, M. Gotoh, S. K. Ikehara, K. Kiyohara, C. Aoki, T. Iwai, H. Nakanishi, et al.
Apical Golgi localization of N,N'-diacetyllactosediamine synthase, {beta}4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa
Glycobiology,
September 1, 2006;
16(9):
777 - 785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Tiedemann, B. Olander, E. Eklund, L. Todorova, M. Bengtsson, M. Maccarana, G. Westergren-Thorsson, and A. Malmstrom
Regulation of the chondroitin/dermatan fine structure by transforming growth factor-{beta}1 through effects on polymer-modifying enzymes
Glycobiology,
December 1, 2005;
15(12):
1277 - 1285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Izumikawa, H. Kitagawa, S. Mizuguchi, K. H. Nomura, K. Nomura, J.-i. Tamura, K. Gengyo-Ando, S. Mitani, and K. Sugahara
Nematode Chondroitin Polymerizing Factor Showing Cell-/Organ-specific Expression Is Indispensable for Chondroitin Synthesis and Embryonic Cell Division
J. Biol. Chem.,
December 17, 2004;
279(51):
53755 - 53761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Kakizaki, K. Kojima, K. Takagaki, M. Endo, R. Kannagi, M. Ito, Y. Maruo, H. Sato, T. Yasuda, S. Mita, et al.
A Novel Mechanism for the Inhibition of Hyaluronan Biosynthesis by 4-Methylumbelliferone
J. Biol. Chem.,
August 6, 2004;
279(32):
33281 - 33289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yada, T. Sato, H. Kaseyama, M. Gotoh, H. Iwasaki, N. Kikuchi, Y.-D. Kwon, A. Togayachi, T. Kudo, H. Watanabe, et al.
Chondroitin Sulfate Synthase-3: MOLECULAR CLONING AND CHARACTERIZATION
J. Biol. Chem.,
October 10, 2003;
278(41):
39711 - 39725.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|